Mozart Relapse Study

NCT00143351 | Completed Phase 3

• 1 other identifier: A1281088
• Study Type: interventional
• Target: 75
• Locations: 1 country
• Sites: 16

Brief Summary

To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of resistant schizophrenic subjects who have benefited from participation in the phase III ziprasidone study A1281039 (MOZART study), to assess the efficacy of ziprasidone in the relapse prevention of schizophrenia, to collect long-term data on safety and tolerability of oral Ziprasidone

Conditions

Schizophrenia

Outcome Measures

Primary Outcomes (1)

• long-term efficacy of oral Ziprasidone in the maintenance treatment

Secondary Outcomes (1)

• To assess the efficacy of ziprasidone in the relapse prevention of schizophrenia To collect long-term data on safety and tolerability of oral Ziprasidone

Interventions

Ziprasidone DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects who have completed MOZART study and who are responders to Ziprasidone:
• Responders: patients with a 20% or more reduction in the PANSS total score at the endpoint of the Mozart Study (recorded at V18 in the Mozart) as compared with the baseline value
• Patients not hospitalised in an acute psychiatric service
• Written, informed consent to participation.
• Female patients of at risk of pregnancy must avoid to remain pregnant; if already used, an adequate method of contraception can be continued

You may not qualify if:

• Psychiatric:
• Subjects with a score of greater than or equal to 5 and an increase of at least 2 points (with respect to baseline value of MOZART study) at one of the following PANSS items: P7 (hostility), G8 (uncooperativeness) or G14 (poor control impulse)
• Subjects with a score equal to 3 and an increase of at least 1 point (with respect to baseline value of MOZART study) at item 8 (suicide) of CDSS
• General:
• Subjects with a history of clinically significant and/or currently relevant haematological, renal (including single kidney), hepatic, gastrointestinal, endocrine (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease), dermatological, oncological, or neurological disease, excluding tardive dyskinesia but including all forms of epilepsy (febrile convulsions in childhood acceptable). The only subjects with known prior malignant disease who are eligible are those with cured prior skin cancer. Controlled Type II diabetes (glucose \< 180 mg/100 ml at screening and baseline with dietary or oral hypoglycemic treatment) will not be considered a significant medical illness and would not exclude a subject from the study
• Patients with a non stabilized somatic disease - Acute or chronic heart disease
• Clinically significant ECG abnormalities
• Subjects with QTc greater than or equal to 500 msec (subjects with QTc greater than or equal to 450 msec and \< 500 msec should be discussed with the cardiologist) - Concomitant treatment with medications that prolong QTc interval (please review prescribing information of other treatments)
• Subjects with serum K+ outside the normal range
• History of seizure (should be discussed with the Sponsor)
• Subject with any confirmed laboratory values that deviate from the upper or lower limits of normal prior to study entry, except for clinically insignificant deviations as determined by investigator
• Pregnant or lactating women
• Subjects who intend to donate blood or blood products during the 4 weeks prior to the study, during the study or in the 30 days after the study ends
• Subjects unable or unlikely to follow the study protocol
• Subjects with a history of neuroleptic malignant syndrome developing from the administration of antipsychotic compounds

Sponsors & Collaborators

• Pfizer's Upjohn has merged with Mylan to form Viatris Inc.: lead

Study Sites (16)

Pfizer Investigational Site

Vicenza, Bassano DEL Grappa, 36061, Italy

Location

Pfizer Investigational Site

Città di Castello, Perugia, 06012, Italy

Location

Pfizer Investigational Site

Bari, 70100, Italy

Location

Pfizer Investigational Site

Brescia, 25100, Italy

Location

Pfizer Investigational Site

Catania, 95123, Italy

Location

Pfizer Investigational Site

Guardiagrele (CH), 66016, Italy

Location

Pfizer Investigational Site

Messina, 98100, Italy

Location

Pfizer Investigational Site

Parma, 43100, Italy

Location

Pfizer Investigational Site

Roma, 00100, Italy

Location

Pfizer Investigational Site

Roma, 00135, Italy

Location

Pfizer Investigational Site

Roma, 00137, Italy

Location

Pfizer Investigational Site

Sassari, 07100, Italy

Location

Pfizer Investigational Site

Terni, Italy

Location

Pfizer Investigational Site

Torino, 10126, Italy

Location

Pfizer Investigational Site

Trieste, 34126, Italy

Location

Pfizer Investigational Site

Verona, 37100, Italy

Location

MeSH Terms

Conditions

Schizophrenia

Interventions

ziprasidone

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2005
• First Posted: September 2, 2005
• Study Start: June 1, 2003
• Study Completion: September 1, 2005
• Last Updated: February 21, 2021

Record last verified: 2021-02

Locations

IT (16)